Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) Stock Competitors & Peer Comparison
See HKPD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HKPD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HKPD | $0.42 | +2.51% | 4.6M | -7.01 | -$0.06 | N/A |
| RPRX | $56.77 | -0.86% | 25.2B | 10.81 | $5.25 | +1.60% |
| CORT | $110.77 | +2.61% | 12B | 316.49 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $90.22 | +0.89% | 8B | 644.43 | $0.14 | N/A |
| KNSA | $76.06 | -0.59% | 5.8B | 84.51 | $0.90 | N/A |
| TRLV | $8.75 | -2.78% | 1.5B | -20.83 | -$0.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| CUVL | $6.68 | -0.65% | 336.6M | N/A | N/A | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
HKPD vs RPRX Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, RPRX has a market cap of 25.2B. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while RPRX trades at $56.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas RPRX's P/E ratio is 10.81. In terms of profitability, HKPD's ROE is -0.14%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, HKPD is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
HKPD vs CORT Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, CORT has a market cap of 12B. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while CORT trades at $110.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas CORT's P/E ratio is 316.49. In terms of profitability, HKPD's ROE is -0.14%, compared to CORT's ROE of +0.08%. Regarding short-term risk, HKPD is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
HKPD vs WBA Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas WBA's P/E ratio is -1.64. In terms of profitability, HKPD's ROE is -0.14%, compared to WBA's ROE of -0.42%. Regarding short-term risk, HKPD is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
HKPD vs LQDA Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, LQDA has a market cap of 8B. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while LQDA trades at $90.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas LQDA's P/E ratio is 644.43. In terms of profitability, HKPD's ROE is -0.14%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, HKPD is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
HKPD vs KNSA Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while KNSA trades at $76.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas KNSA's P/E ratio is 84.51. In terms of profitability, HKPD's ROE is -0.14%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, HKPD is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check KNSA's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
HKPD vs TRLV Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while TRLV trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas TRLV's P/E ratio is -20.83. In terms of profitability, HKPD's ROE is -0.14%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, HKPD is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check TRLV's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
HKPD vs HROWL Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas HROWL's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.14%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, HKPD is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
HKPD vs HROWM Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas HROWM's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.14%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, HKPD is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check HROWM's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
HKPD vs CUVL Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, CUVL has a market cap of 336.6M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while CUVL trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas CUVL's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.14%, compared to CUVL's ROE of N/A. Regarding short-term risk, HKPD is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check CUVL's competition here
LifeMD, Inc. (NASDAQ: LFMD)
HKPD vs LFMD Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, LFMD has a market cap of 172.2M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while LFMD trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas LFMD's P/E ratio is -7.12. In terms of profitability, HKPD's ROE is -0.14%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, HKPD is less volatile compared to LFMD. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check LFMD's competition here
LifeMD, Inc. (NASDAQ: LFMDP)
HKPD vs LFMDP Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, LFMDP has a market cap of 160M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while LFMDP trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas LFMDP's P/E ratio is -722.96. In terms of profitability, HKPD's ROE is -0.14%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, HKPD is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check LFMDP's competition here
Circle8 Group, Inc. (NASDAQ: CIRC)
HKPD vs CIRC Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, CIRC has a market cap of 65.1M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while CIRC trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas CIRC's P/E ratio is -1.64. In terms of profitability, HKPD's ROE is -0.14%, compared to CIRC's ROE of +0.00%. Regarding short-term risk, HKPD is less volatile compared to CIRC. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check CIRC's competition here
Rite Aid Corporation (NYSE: RAD)
HKPD vs RAD Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas RAD's P/E ratio is -0.05. In terms of profitability, HKPD's ROE is -0.14%, compared to RAD's ROE of +2.76%. Regarding short-term risk, HKPD is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
HKPD vs GLTO Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas GLTO's P/E ratio is -1.78. In terms of profitability, HKPD's ROE is -0.14%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, HKPD is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check GLTO's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
HKPD vs SCYX Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, SCYX has a market cap of 33M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while SCYX trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas SCYX's P/E ratio is -1.53. In terms of profitability, HKPD's ROE is -0.14%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, HKPD is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check SCYX's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
HKPD vs NSRX Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, NSRX has a market cap of 29.8M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while NSRX trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas NSRX's P/E ratio is -4.80. In terms of profitability, HKPD's ROE is -0.14%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, HKPD is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check NSRX's competition here
Stablecoin Development Corp. (AMEX: SDEV)
HKPD vs SDEV Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, SDEV has a market cap of 28.2M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while SDEV trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas SDEV's P/E ratio is -0.18. In terms of profitability, HKPD's ROE is -0.14%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, HKPD is more volatile compared to SDEV. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check SDEV's competition here
Biofrontera Inc. (NASDAQ: BFRI)
HKPD vs BFRI Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, BFRI has a market cap of 16.3M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while BFRI trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas BFRI's P/E ratio is -1.19. In terms of profitability, HKPD's ROE is -0.14%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, HKPD is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
HKPD vs CJJD Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas CJJD's P/E ratio is -0.46. In terms of profitability, HKPD's ROE is -0.14%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, HKPD is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
HKPD vs SSY Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas SSY's P/E ratio is -2.86. In terms of profitability, HKPD's ROE is -0.14%, compared to SSY's ROE of -0.09%. Regarding short-term risk, HKPD is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
HKPD vs POM Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, POM has a market cap of 5.9M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while POM trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas POM's P/E ratio is -0.17. In terms of profitability, HKPD's ROE is -0.14%, compared to POM's ROE of +0.16%. Regarding short-term risk, HKPD is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check POM's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
HKPD vs PAVS Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, PAVS has a market cap of 5.3M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while PAVS trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas PAVS's P/E ratio is -0.07. In terms of profitability, HKPD's ROE is -0.14%, compared to PAVS's ROE of -0.27%. Regarding short-term risk, HKPD is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check PAVS's competition here
AIxCrypto Holdings, Inc. (NASDAQ: AIXC)
HKPD vs AIXC Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, AIXC has a market cap of 4.3M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while AIXC trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas AIXC's P/E ratio is -0.09. In terms of profitability, HKPD's ROE is -0.14%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, HKPD is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check AIXC's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
HKPD vs MDVL Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas MDVL's P/E ratio is -0.05. In terms of profitability, HKPD's ROE is -0.14%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, HKPD is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
HKPD vs ATNFW Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas ATNFW's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.14%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, HKPD is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
HKPD vs BGMSP Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, HKPD's ROE is -0.14%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, HKPD is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check BGMSP's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
HKPD vs BGMS Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while BGMS trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas BGMS's P/E ratio is -0.26. In terms of profitability, HKPD's ROE is -0.14%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, HKPD is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check BGMS's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
HKPD vs AZNH Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas AZNH's P/E ratio is 38.35. In terms of profitability, HKPD's ROE is -0.14%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, HKPD is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
HKPD vs LFLYW Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, HKPD's ROE is -0.14%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, HKPD is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check LFLYW's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
HKPD vs SBFMW Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while SBFMW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas SBFMW's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.14%, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, HKPD is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check SBFMW's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
HKPD vs ESRX Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas ESRX's P/E ratio is 10.69. In terms of profitability, HKPD's ROE is -0.14%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, HKPD is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check ESRX's competition here
POZEN Inc. (NASDAQ: POZN)
HKPD vs POZN Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, POZN has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas POZN's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.14%, compared to POZN's ROE of +0.61%. Regarding short-term risk, HKPD is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check POZN's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
HKPD vs OREX Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, OREX has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas OREX's P/E ratio is -0.14. In terms of profitability, HKPD's ROE is -0.14%, compared to OREX's ROE of -0.54%. Regarding short-term risk, HKPD is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check OREX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
HKPD vs IPXL Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas IPXL's P/E ratio is -10.11. In terms of profitability, HKPD's ROE is -0.14%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, HKPD is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for HKPD.Check IPXL's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
HKPD vs CPD Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, CPD has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas CPD's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.14%, compared to CPD's ROE of N/A. Regarding short-term risk, HKPD is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
HKPD vs SHPG Comparison August 2026
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 4.6M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.42 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of -7.01, whereas SHPG's P/E ratio is 11.35. In terms of profitability, HKPD's ROE is -0.14%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, HKPD is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for HKPD.Check SHPG's competition here